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Abstract: Patients with metastatic gastric cancer have a poor outcome. The development of 
new combinations of chemotherapy has led to steady but only modest gains in overall survival 
with largest effects reported with two- and three-drug regimens. Trastuzumab, a fully   humanized 
monoclonal antibody directed at the human epidermal growth factor receptor-2 (HER2), has 
been found to improve response rate and survival in patients with advanced gastric cancer. 
This update will review the role of HER2 and summarize therapeutic advances in the use of 
trastuzumab in advanced gastric cancer.
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Introduction
In 2010, it is estimated that 21,000 men and women will be diagnosed with gastric 
cancer in the United States. During the same year, 10,570 will die of this disease. 
Worldwide, gastric cancer is the fourth most common cancer and the second most 
common cause of cancer death. The incidence of cardiac and gastroesophageal tumors 
has increased dramatically, while cancers in the distal half of the stomach have declined 
in the United States since the 1930s. Additionally, patient demographics have shifted 
with a marked increase in incidence in younger patients. With approximately 80% of 
patients presenting with advanced disease, palliative chemotherapy plays an essential 
role in the treatment of these cancers.1
Gastric cancer remains highly fatal with only modest gains in survival having been 
achieved with modern chemotherapy. To date, there is no standard chemotherapeutic 
option for patients with metastatic gastric cancer. Cisplatin and 5-fluorouracil   typically 
combined with either a taxane2 or an anthracycline3 comprise the most common 
  treatment regimens.
Targeted therapy, including inhibitors of the vascular endothelial and   epidermal 
growth factor receptors, appears to be promising. Human epidermal growth   factor 
receptor-2 (ErbB2 or HER2) is a well-established target that has been   studied 
  extensively in gastric cancer. Trastuzumab (Herceptin®, F. Hoffman-La Roche, 
Basel, Switzerland), a fully humanized monoclonal antibody directed against 
HER2, is a s  tandard therapy for patients with HER2 positive breast cancer, after 
studies   demonstrated improved survival and response rates.4 This review will 
focus on the role of HER2 and its inhibition with trastuzumab in advanced gastric 
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The human epidermal growth 
factor receptor-2 (HER2)
Epidermal growth factor and its receptor (EGFR or ErbB) 
were initially discovered in 1962 and 1978, respectively.5 
The ErbB family consists of four closely related type 1 
transmembrane tyrosine kinase receptors: ErbB1 (EGFR or 
HER1), ErbB2 (HER2), ErbB3 (HER3), and ErbB4 (HER4). 
Each receptor is a transmembrane protein comprising an 
extracellular domain at which ligand binding occurs, an 
alpha-helical transmembrane segment, and an intracellular 
protein tyrosine kinase domain. Ligand binding to these EGF 
family receptors phosphorylates and activates a complex 
intracellular signaling network, which controls a range of 
cellular processes including proliferation, angiogenesis, cell 
cycle, survival, and apoptosis.6
HER2 was the second receptor discovered in this 
  family. Structurally, HER2 is a 185 kD glycoprotein and a 
product of the c-erbB-2/neu oncogene. As opposed to the 
other members of the EGFR family, no ligand has been 
linked to HER2. Researchers believe that the receptor must 
homodimerize independently of a ligand, or heterodimerize 
with another ligand-bound member of the EGFR family for 
activation. Ligand-independent homodimerization will occur 
in the setting of HER2 overexpression.7 Activation leads 
to autophosphorylation of the intracellular tyrosine kinase 
domain and downstream signaling of the RAS, MAP, and 
P13K pathways. HER2 amplification and   overexpression 
plays a central role in disease initiation, progression, and 
metastasis, and is traditionally associated with a worse 
  prognosis in patients with breast and gastric cancers.8
HER2 in gastric cancer
Amplification of HER2 was described in a gastric 
  cancer cell line initially in 1986.9 In 1991, initial   clinical 
findings were published by Yonemura and colleagues 
documenting HER2 overexpression to be detected by 
  immunohistochemistry in 11.9% of 260 Japanese gastric 
cancer patients.10 Many   subsequent studies have found 
amplification or   overexpression of HER2 in 7% to 34% of 
gastric carcinomas.11–16   Histologically, HER2 overexpression 
is more often   associated with differentiated tumors17,18 as well 
as intestinal-type tumors11–15,19 both of which would imply a 
more favorable outcome. In the ToGA trial,14 which will be 
discussed later, HER2 overexpression was far more common 
in intestinal-type (75%) than diffuse-type (9%) tumors. The 
correlation of intestinal-type histology and HER2 overexpres-
sion is not well understood but may be partially explained by 
E-cadherin mutations. In gastric cancer, HER2 gene ampli-
fication associates inversely with E-cadherin   mutations20 
which are more common in diffuse-type gastric and lobular 
invasive breast carcinomas and rare in intestinal-type gastric 
and ductal invasive breast   carcinomas.13 In addition, ger-
mline mutations of E-cadherin have been identified that are 
responsible for a dominantly inherited from of diffuse-type 
gastric cancer.21 However, HER2 overexpression is more 
often associated with higher T-stage and nodal involvement 
at time of diagnosis,17 which are poor prognostic factors. 
HER2 overexpressing tumors are most often in the located 
gastroesophageal junction (33.2%) rather than the remainder 
of the stomach (20.9%).14
Historically, HER2 overexpression was associated with a 
significantly worse overall survival. Multiple series confirm 
these findings.13,15,17,19,22–25 However, a recently published 
European11 series as well as two Asian series16,18 found that 
HER2 overexpression does not impact prognosis. Indeed, 
the patients treated in the chemotherapy alone arm of the 
ToGA trial14 survived to a median of 11.1 months, which is 
equivalent if not superior to historic comparisons. Therefore, 
the impact of HER2 overexpression on survival remains 
unclear, and arguably has little impact.
There has been a concerted effort to standardize HER2 
assessment in gastric carcinoma. Compared with breast car-
cinoma, HER2 immunoreactivity in gastric carcinoma is more 
incomplete and heterogeneous. Additionally, HER2 staining 
results appear to differ by type of specimen, ie, endoscopic 
biopsy compared with surgically resected specimens.11 
  Hoffman and colleagues12 have developed and validated a 
scoring system for assessing HER2 in gastric carcinomas. 
  Assessment of 168 resection specimens (149 from the stomach 
and 16 from the gastroesophageal junction) was performed 
using immunohistochemistry by HecepTest™ (Dako,   Denmark) 
and fluorescence in-situ hybridization (FISH) by HER2 FISH 
(pharmDx™, Dako, Denmark). Twenty-nine samples were 
considered FISH positive (defined as HER2:CEP17 ratio $2), 
while 18 samples were considered positive with IHC 3+. 
All 18 samples positive by IHC were positive by FISH, 
however FISH identified another 11 patients which were 
considered negative (IHC 0 or 1+) or equivocal (IHC 2+). 
Discrepancies between IHC and FISH results were attributed 
to basolateral membranous immunoreactivity of glandular cells 
resulting in incomplete membranous reactivity along with a 
higher rate of tumor   heterogeneity. Based on the   findings of 
this study, a   consensus panel has proposed   recommendations 
on HER2 scoring for gastric cancer (Table 1).OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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Clinical trials using trastuzumab
The results of a study combining trastuzumab with cisplatin 
in HER2 positive untreated patients with gastric cancer 
have recently been presented.26 Twenty-one patients with 
advanced gastric or gastroesophageal carcinoma were 
enrolled. Overall the response rate was reported at 35% 
in 17 evaluable patients with final results on survival not 
available yet. Another study evaluating the role of trastu-
zumab in the treatment of previously untreated advanced 
gastric cancer in combination with cisplatin and docetaxel is 
underway with evidence of preliminary activity.27 Our group 
recently published results of a phase I study evaluating the 
safety profile of interleukin-12 when given in combination 
with trastuzumab and paclitaxel to patients with metastatic 
HER2-overexpressing cancers.28 Twenty-one patients were 
enrolled, four with metastatic gastro-esophageal and two 
with metastatic gastric adenocarcinomas. The only patients 
who experienced benefit on this study were those with a 
diagnosis of breast cancer or gastric/gastro-esophageal 
cancer. Two of the four patients with metastatic esophageal 
adenocarcinoma achieved a partial response lasting 25 and 
43 weeks, respectively. One of the two patients with gastric 
cancer maintained stable disease for 62 weeks.
The only randomized controlled study evaluating the 
activity of trastuzumab in the first-line treatment of HER2 
positive advanced gastric and gastroesophageal carcinoma 
is the recently published Phase III ToGA trial.14 This open-
label, randomized controlled trial enrolled patients from 
24 countries. In this study, 3807 patients with gastric and 
gastroesophageal adenocarcinoma were screened for HER2 
overexpression, defined as IHC 3+ or FISH positive (+) as 
established in the Hoffman trial.12 Five hundred and eighty-
four patients were randomized to receive cisplatin 80 mg/m2 
on 1 day with either 5-fluorouracil 800 mg/m2 on days 1–5 
or capecitabine 2000 mg/m2 on days 1–14 alone or in 
  combination with trastuzumab 8 mg/kg on day 1 f  ollowed by 
6 mg/kg administered every 3 weeks until disease   progression. 
The protocol allowed patients who completed six cycles of 
chemotherapy and trastuzumab to continue on trastuzumab 
monotherapy until disease progression. The   primary end 
point was overall survival and   secondary end points included 
progression-free survival, time to   progression, response rate, 
duration of response and safety.
Two hundred and ninety-six patients were   randomized to the 
chemotherapy alone arm and 298 patients to the   chemotherapy 
and trastuzumab arm. Median follow-up was 18.6 months 
in the trastuzumab plus chemotherapy arm and 17.1 months 
in the chemotherapy alone arm. The study met its primary 
endpoint with a median overall survival of 13.8 months 
in the   chemotherapy with trastuzumab arm compared 
with 11.1 months in the chemotherapy alone arm (P = 0.0046). 
All other efficacy parameters were also significantly improved 
with the addition of trastuzumab to chemotherapy compared 
with chemotherapy alone (Table 2). It should be noted that the 
control arm group fared better than historic comparisons. This 
result may be related to the large proportion of Asian patients 
enrolled in the study, or more likely the presence of a high rate of 
intestinal-type histology in the study population. Seventy-seven 
percent of the experimental group and 74% of the control group 
were found to have intestinal-type histology, which is typically 
associated with better prognosis than diffuse-type histology. 
Unlike previously published data,11,16,18 these findings suggest 
that tumors overexpressing HER2 may have an equivalent if 
not favorable prognostic effect.
Therapy was very well tolerated with expected   hematologic 
and gastrointestinal toxicities. The most common side effects 
were nausea, vomiting, and neutropenia. Patients assigned 
to trastuzumab plus chemotherapy had slightly higher rates 
Table 1 HER2 immunohistochemical staining classification
Surgical specimen staining pattern  Biopsy specimen staining pattern  Classification/score
No reactivity or membranous reactivity  
in ,10% of tumor cells
No reactivity or no membranous reactivity  
in any tumor cell 
Negative/0 
Faint or barely perceptible membranous 
reactivity in $10% of tumor cells; cells 
are reactive only in part of membrane
Tumor cell cluster with faint or barely perceptible  
membranous reactivity irrespective of percentage  
of tumor cells stained
Negative/1+ 
weak to moderate complete, 
basolateral or lateral membranous reactivity  
in $10% of tumor cells 
Tumor cell cluster with a weak to moderate complete,  
basolateral or lateral membranous reactivity irrespective  
of percentage of tumor cells stained
equivocal/2+ 
Strong complete, basolateral or lateral 
membranous reactivity in $10% of tumor cells 
Tumor cell cluster with a strong complete, basolateral  
or lateral membranous reactivity irrespective of  
percentage of tumor cells stained 
Positive/3+ 
Copyright © 2008. John wiley and Sons. Adapted with permission from Hofmann M, Stoss O, Shi D, et al. Assessment of a HeR2 scoring system for gastric cancer: results from 
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of diarrhea, stomatitis, anemia, thrombocytopenia, fatigue, 
chills, weight loss, pyrexia, mucositis, and nasopharyngitis. 
With the exception of diarrhea, rates of grade 3 and 4 adverse 
events as well as cardiac adverse events were similar between 
the groups. Eleven patients (5%) experienced a $10% 
decrease in left ventricular ejection fraction, and up to ,50% 
in the trastuzumab and chemotherapy group compared, with 
two patients (1%) in the chemotherapy alone group. The 
addition of trastuzumab to chemotherapy did not adversely 
affect quality of life.29
Future directions
The use of trastuzumab in gastric carcinomas is in its infancy 
and many avenues await exploration. As discussed previously, 
in advanced gastric carcinoma, trastuzumab has only been 
studied in combination with cisplatin and 5-FU in the Phase 
III setting, leading to FDA approval in the United States. 
However, in advanced HER2-overexpressing breast cancers, 
trastuzumab is very active in combination with taxanes, a class 
of chemotherapy active in gastric carcinoma.30–32 A pivotal 
Phase III trial published in 2001 combined trastuzumab with 
paclitaxel in patients with breast cancer previously treated 
with anthracyclines.4 In comparison to single-agent paclitaxel, 
the combination of paclitaxel and trastuzumab was associated 
with a significantly higher response rate of 38% vs 16% 
as well as a 4-month improvement in time to progression. 
There was also a nonsignificant increase in overall survival 
from 18 to 22 months. In addition, multiple Phase II studies 
have suggested superiority of the combination of docetaxel 
and trastuzumab compared with docetaxel alone.33–35 Many 
consider the combination of a taxane and trastuzumab to 
represent the best first-line option for women with hormone 
refractory HER2-overexpressing metastatic breast cancer. 
In our opinion, similar findings will be found in HER2-
overexpressing gastric carcinomas, but we cannot endorse 
the use of trastuzumab with taxanes in the absence of data. 
Currently, an ongoing Phase II clinical trial is   evaluating 
trastuzumab in combination with docetaxel, cisplatin, and 
5-FU (ClinicalTrials.gov number NCT00515411) which 
may shed some light on this subject. Agents being evaluated 
in combination with trastuzumab for advanced gastric 
carcinomas include capecitabine and oxaliplatin, cisplatin 
and TS-One, and bevacizumab among others.
Resistance to trastuzumab will invariably develop in 
patients with advanced cancers being treated with trastuzumab-
containing regimens. Indeed, the rate of primary resistance to 
single-agent trastuzumab in HER2-overexpressing metastatic 
breast carcinomas is 66%–88%.36–38 The conventional 
wisdom of discontinuing a cytotoxic agent upon progression 
has yet to be elucidated for novel biologics, and whether 
trastuzumab treatment should be continued upon progression 
with a different chemotherapeutic agent has not yet been 
established. Just as we do not fully understand the mechanisms 
of action of trastuzumab, we have even less understanding 
of the mechanisms of resistance. Proposed mechanisms of 
  resistance include activation of multiple downstream   signaling 
pathways such as P13K/AKT pathway which may occur 
with or without loss of the PTEN tumor suppressor gene,39 
activation of non-HER2 receptors such as insulin-like growth 
factor-I,40 disruption of the interaction between the therapeutic 
agent and the target protein through increased expression of 
membrane-associated glycoprotein (MUC4),41 and loss of the 
binding site on   truncated HER2 receptors.42 Retrospective 
studies suggest that trastuzumab   administration is indicated 
after disease   progression attributed to an increase in response 
rate as well as survival. A systematic review revealed that the 
response rate of second-line therapy along with   continuation 
of trastuzumab was 21% with a time to progression of 
6.7 months which appear promising.43 A recently published 
observational of study of 623 patients found the median time to 
progression was longer in patients who continued trastuzumab 
beyond progression (10.2 months) than in those who stopped 
(7.1 months).44 Attempts to answer this   question via phase III 
trials have been unsuccessful, plagued by slow accrual out 
of reluctance by caregivers and patients to   discontinue 
  trastuzumab. SWOG 0347 as well as the   German Breast Group 
26/Breast   International Group 03–0545 studies were closed 
early, secondary to poor accrual. In the latter trial, analysis of 
Table 2 Results of trastuzumab in combination with chemotherapy vs chemotherapy alone for treatment of HeR2 positive advanced 
gastric or gastro-esophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial
Trastuzumab plus chemotherapy  Chemotherapy alone  P value (nonstratified) 
Overall survival  13.8 months 11.1 months 0.0046
Progression-free survival  6.7 months  5.5 months  0.0002 
Time to progression  7.1 months  5.6 months  0.0003 
Duration of response  6.9 months  4.8 months  ,0.0001 
Overall response rate  47%  35%  0.00175 OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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156 of a planned 482 patients revealed a response rate of 27% 
and 48% in patients who stopped and continued trastuzumab, 
respectively. Trastuzumab use beyond   progression was 
  associated with a 31% reduction of tumor progression and 
increase in time to progression of 2.5 months. No studies have 
addressed this question in gastric carcinoma.
Lapatinib (GlaxoSmithKline, Research Triangle Park, 
NC, USA), an oral small molecule dual tyrosine kinase 
inhibitor of EGFR and HER2, has been found to be active 
in HER2-overexpressing cancers. In those with trastuzumab-
refractory breast cancer, lapatinib combined with capecit-
abine had a response rate of 22% and statistically improved 
time to progression from 4.4 months in the lapatanib alone 
group to 8.4 months in the combination arm.46 Lapatinib 
in combination with chemotherapy is being assessed in 
advanced gastric carcinoma. The Phase III LOGiC trial 
(NCT00680901) is evaluating the combination of lapatinib 
in combination with capecitabine and oxaliplatin for first-
line HER2-overexpressing gastric carcinomas. The study is 
actively accruing patients and no efficacy results are available 
to date. Safety analysis from TYTAN, a Phase III Asian study 
of lapatinib in combination with paclitaxel as second-line 
therapy in HER2 overexpressing gastric cancer, revealed no 
safety issues.47 Efficacy results are not yet available.
This review has focused on advanced disease. As seen 
in breast cancer, trastuzumab is an integral part of adjuvant 
or neoadjuvant treatment of operable disease. Perioperative 
chemotherapy using epirubicin, cisplatin, and 5-fluorouracil 
has been shown to improve survival in operable disease over 
surgery alone.48 A recent Phase III study, RTOG 1010, is 
  evaluating the addition of trastuzumab to trimodality treatment 
of HER2-overexpressing esophageal adenocarcinoma.
Conclusion
HER2 overexpression in gastric cancer has been traditionally 
associated with poor survival, although results from recent 
studies such as the ToGA trial, appear to contradict this. HER2 
targeted therapy with trastuzumab, when combined with che-
motherapy (cisplatin and a fluoropyrimidine) has been shown 
to improve response rate, and progression-free and overall 
survival compared with chemotherapy alone in patients with 
advanced gastric or gastroesophageal adenocarcinomas, which 
overexpress HER2 (IHC 3+ and/or FISH+). In addition to 
improved outcome, trastuzumab combined with chemotherapy 
was found to be tolerable with no negative impact on quality 
of life. As such, trastuzumab should play an integral part in the 
management of patients with HER2-overexpressing advanced 
gastric adenocarcinoma. Current studies are evaluating the role 
of this combined approach in the perioperative setting. Future 
studies are needed to address the question of how to proceed 
upon disease progression while on trastuzumab.
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